Abstract 357P
Background
Advanced Head and neck cancer despite multimodal treatment is associated with disfigurement, extreme pain, and psychological distress. To study the effects of a multimodal palliative approach involving psychological counselling, psychometric dug therapy and pain-relieving blocks to ameliorate the total pain state of such patient during end of life care.
Methods
This is a prospective, single-arm observational study conducted on 20 head and neck cancer patients, from January 2015 to December 2018. Patients who were on palliative treatment were processed for self-report of severe psychological distress and intractable pain by means of innovative distress score and quality of life index and the numeric pain rating scale and given combination therapy with antidepressants, antipsychotics, pain killers and neurolytic blocks along with repeated counselling sessions.
Results
20 patients were included in this study, of which 66.6 % were males and 33.3% were female. Age range was 44-79 years and they had mean pain scores of 7.61 (SD 1.577) before the intervention and mean distress scores of 8.33 (SD 1.237) suffering for a duration of 72.5 days (SD 24.81). A significant reduction in pain was noted by a decrease in mean Numeric rating scale to 2.83 (SD 0.618) and extension of the mean duration of analgesia to 24.33 days (SD 6.84) and reduction in distress score to 3.78 (SD 0.732). Pre- and post-procedure mean morphine requirement was also significantly reduced, at the end of 2 weeks. Significant easing of distress and improvement in performance was observed in all patients.
Conclusions
The application of a multimodal palliative approach to progressive head and neck cancer patients is an easy, safe, and cost-effective method to improve quality of life. Medical oncologists must be sensitized to elicit and measure the distress in such patients. Counseling sessions and pharmacotherapy, if indicated, are very effective in the care of such patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract